Literature DB >> 30390562

Distribution kinetics of puerarin in rat hippocampus after acute local cerebral ischemia.

Hui Kong1, Guiliang Zhang1, Jinjun Cheng1, Rongfeng Shi1, Meiling Zhang1, Peng Cao1, Yan Zhao2, Huihua Qu3, Qingguo Wang4.   

Abstract

Puerarin, isolated from the roots of Pueraria lobata, is widely used for treating cerebral ischemia in China. The time- and dose-dependent distribution characteristics of puerarin in the ischemic hippocampus are unknown. In this study, puerarin concentration was determined by an indirect competitive ELISA using anti-puerarin monoclonal antibody. Area under the curve (AUC0-120 min) of puerarin (80 mg/kg) in the embolic hippocampus was higher than that in the normal hippocampus; the increase was significant only at 40 and 20 mg/kg. The maximum concentration (Cmax) of puerarin in the embolic hippocampus was higher than that in the normal hippocampus at all doses. The increase in both AUC0-120 min and Cmax was dose-dependent. Time to reach the maximum concentration (Tmax) of puerarin in the embolic and normal hippocampus was similar. Although the mean residence time in the embolic hippocampus differed from that in the normal hippocampus at 40 and 80 mg/kg, it was higher in the embolic hippocampus than in the normal hippocampus at 20 mg/kg. This is the first study to report that the time- and dose-dependent distribution characteristics of puerarin in the normal and embolic hippocampus after middle cerebral artery occlusion in rats dictate puerarin dose and duration to treat stroke.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Acute local cerebral ischemia; Hippocampus; Indirect competitive enzyme-linked immunosorbent assay; Pharmacokinetics; Puerarin; Tissue distribution

Mesh:

Substances:

Year:  2018        PMID: 30390562     DOI: 10.1016/j.jpba.2018.10.038

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  6 in total

1.  Combination of puerarin and tanshinone IIA alleviates ischaemic stroke injury in rats via activating the Nrf2/ARE signalling pathway.

Authors:  Qing Miao; Ruihai Wang; Xiaoxin Sun; Song Du; Limei Liu
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

2.  Neuroprotective Mechanisms of Puerarin in Central Nervous System Diseases: Update.

Authors:  Chao-Chao Yu; Yan-Jun Du; Jin Li; Yi Li; Li Wang; Li-Hong Kong; Ying-Wen Zhang
Journal:  Aging Dis       Date:  2022-07-11       Impact factor: 9.968

3.  Puerarin protects cardiomyocytes from ischemia-reperfusion injury by upregulating LncRNA ANRIL and inhibiting autophagy.

Authors:  Yanhui Han; Honglei Wang; Yan Wang; Pingshuan Dong; Jingjing Jia; Shaohui Yang
Journal:  Cell Tissue Res       Date:  2021-05-08       Impact factor: 5.249

Review 4.  Effects of puerarin on chronic inflammation: Focus on the heart, brain, and arteries.

Authors:  Li Zhang; Lisheng Liu; Mingyi Wang
Journal:  Aging Med (Milton)       Date:  2021-12-15

5.  Puerarin Attenuates Oxidative Stress and Ferroptosis via AMPK/PGC1α/Nrf2 Pathway after Subarachnoid Hemorrhage in Rats.

Authors:  Yi Huang; Honggang Wu; Yongmei Hu; Chenhui Zhou; Jiawei Wu; Yiwen Wu; Haifeng Wang; Cameron Lenahan; Lei Huang; Sheng Nie; Xiang Gao; Jie Sun
Journal:  Antioxidants (Basel)       Date:  2022-06-27

Review 6.  Pharmacokinetics and drug delivery systems for puerarin, a bioactive flavone from traditional Chinese medicine.

Authors:  Liang Zhang
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.